Success Metrics

Clinical Success Rate

44.4%

Based on 4 completed trials

Completion Rate

44%(4/9)

Active Trials

0(0%)

Results Posted

125%(5 trials)

Terminated

5(56%)

Phase Distribution

Ph phase_3

56%

Ph phase_2

44%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 2Efficacy & side effects

4(44.4%)

Phase 3Large-scale testing

5(55.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

44.4%

4 of 9 finished

Non-Completion Rate

55.6%

5 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(5)

Detailed Status

Terminated5

Completed4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

44.4%

Most Advanced

Phase 3

Trials by Phase

Phase 24 (44.4%)

Phase 35 (55.6%)

Trials by Status

completed444%

terminated556%

Recent Activity

0 active trials

Showing 5 of 9

terminatedphase_3

Clinical Trials (9)

Showing 9 of 9 trials

NCT02768662Phase 3

A 6-Month Extension Study of OTO-104 in Meniere's Disease

Terminated

NCT02717442Phase 3

Study of OTO-104 in Subjects With Unilateral Meniere's Disease

Terminated

NCT02612337Phase 3

Study of OTO-104 in Subjects With Unilateral Meniere's Disease

Completed

NCT02706730Phase 3

A 6-Month Extension Study of OTO-104 in Meniere's Disease

Terminated

NCT03664674Phase 3

Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease

Completed

NCT02997189Phase 2

Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss

Terminated

NCT02740387Phase 2

Open Label Study of OTO-104 in Subjects With Meniere's Disease

Terminated

NCT02265393Phase 2

A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom

Completed

NCT01412177Phase 2

OTO-104 for the Treatment of Meniere's Disease

Completed

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9